Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort
Table 3
Self-reported on-study fracture among nonpharmacologically treateda POSSIBLE US subjects stratified by the National Osteoporosis Foundation treatment thresholds.
Number of subjects with FRAX score
FRAX predicted 10-year risk of ≥3% for hip fracture
FRAX predicted 10-year risk of ≥20% for major osteoporotic fracture
FRAX score ≥ intervention threshold for either hip or major osteoporotic fractures
( = 1,299) n (%)
Yes ( = 407) n (%)
No ( = 892) n (%)
P value
Yes ( = 206) n (%)
No ( = 1,093) n (%)
P value
Yes ( = 411) n (%)
No ( = 888) n (%)
P value
No on-study fracture
1,227 (94.5)
384 (94.4)
843 (94.5)
0.91
192 (93.2)
1,035 (94.7)
0.39
388 (94.4)
839 (94.5)
0.95
Any on-study fracture
72 (5.5)
23 (5.7)
49 (5.5)
14 (6.8)
58 (5.3)
23 (5.6)
49 (5.5)
Any osteoporosis- related fracture
47 (3.6)
18 (4.4)
29 (3.3)
0.29
12 (5.8)
35 (3.2)
0.06
18 (4.4)
29 (3.3)
0.33
Hip fracture
9 (0.7)
3 (0.7)
6 (0.7)
0.90
1 (0.5)
8 (0.7)
0.70
3 (0.7)
6 (0.7)
0.91
Spine fracture
9 (0.7)
4 (1.0)
5 (0.6)
0.40
4 (1.9)
5 (0.5)
0.02
4 (1.0)
5 (0.6)
0.41
Nonhip/non- spine fracture
31 (2.4)
11 (2.7)
20 (2.2)
0.61
7 (3.4)
24 (2.2)
0.30
11 (2.7)
20 (2.3)
0.64
Multiple osteoporosis- related fractures
11 (0.9)
6 (1.5)
5 (0.6)
0.10
4 (1.9)
7 (0.6)
0.06
6 (1.5)
5 (0.6)
0.10
Subjects who reported no pharmacological therapy or using only calcium/vitamin D within 2 months of study entry. P value is for pairwise (yes/no) comparisons with percentage of specified fracture risk outcome for each risk category.
